|
Originally published In Press as doi:10.1074/jbc.M204721200 on June 13, 2002
J. Biol. Chem., Vol. 277, Issue 33, 29760-29764, August 16, 2002
The Human Acid -Glucosidase Gene Is a Novel Target of the
Notch-1/Hes-1 Signaling Pathway*
Bo
Yan ,
Nina
Raben, and
Paul
Plotz§
From the Arthritis and Rheumatism Branch, NIAMS, National
Institutes of Health, Bethesda, Maryland 20892-1820
Received for publication, May 14, 2002, and in revised form, June 12, 2002
 |
ABSTRACT |
Acid -glucosidase (GAA) is a lysosomal enzyme
that degrades glycogen. A deficiency of GAA is responsible for a
recessively inherited myopathy and cardiomyopathy, glycogenosis type
II. Previously, we identified an intronic repressor element in
the GAA gene and demonstrated that Hes-1, a basic
helix-loop-helix factor, binds to a C class E box within the element
and functions as a transcriptional repressor in HepG2 cells.
Hes-1 is a well studied downstream target gene in the Notch
signaling pathway. In this study, over-expression and depletion of
Notch-1 intracellular domain (NICD) strategies were used to investigate
whether expression of the GAA gene is under the control of
Notch-1/Hes-1 signaling. In co-transfection experiments, Hes-1,
up-regulated by over-expressed NICD, enhanced the repressive effect of
the DNA element with wild type Hes-1 binding sites but not with mutant
Hes-1 binding sites. Conversely, depletion of Notch-1 with
phosphorothioated antisense oligonucleotides, corresponding to the
fourth ankyrin repeat within NICD, led to reduced Hes-1. Constitutively
over-expressed Hes-1 and Notch-1 repressed GAA gene
expression. Therefore, our data establish that the human
GAA gene, encoding a lysosomal enzyme, is a downstream target of the Notch-1/Hes-1 signaling pathway.
 |
INTRODUCTION |
Notch receptors, members of a transmembrane protein family, play
essential roles in cell fate decision in several developmental processes from Drosophila to human (1-3). Four Notch
receptors (Notch 1-4) and four ligands (Jagged-1, Jagged-2, and
Delta-like 1 and 3) have been identified in mammals. The biochemical
mechanisms of Notch signaling are conserved among the Notch receptors
(4). Upon activation by Notch ligands, Notch intracellular domain
(NICD)1 is cleaved, released
from the whole receptor, and translocated into the nucleus. There it
forms a complex with DNA-binding protein RBP-Jk
(CSL/CBF1/Su(H)/Lag-1) and directly
activates transcription of its downstream target genes (5-8).
Hes, the mammalian homologues of Drosophila hairy and
Enhancer of Split proteins are basic helix-loop-helix proteins,
which function as transcriptional factors (9). Among Hes family
members, Hes-1, -2, -3, -5,
-6, and -7 genes have been isolated in mammals (10-15). The Hes-1 gene has been established as a
downstream target of Notch signaling (16-18). Like Notch receptors,
Hes-1 is also essential to several developmental processes such as
neurogenesis, myogenesis, hematopoiesis, and T cell development (19),
and additional functions of this transcription factor continue to be
reported (20, 21). As a transcriptional repressor, Hes-1 down-regulates
its target genes, such as Mash-1 and CD4 genes, by binding to a C class E box (CANNTG) or an N box (CACNAG) (22-24). Transducin-like enhancer (TLE), a mammalian homolog of the
Drosophila Groucho, interacts with Hes-1 as a co-repressor
(25).
Acid -glucosidase (GAA; acid maltase, EC 3.2.1.20) is a
glycogen-degrading lysosomal enzyme, a deficiency of which causes glycogen storage disease type II (GSDII, also called Pompe's disease or acid maltase deficiency), a recessively inherited muscle disease (26). GAA belongs to a large family of lysosomal enzymes. The regulation of this gene, as well as that of other lysosomal enzyme genes, is largely unknown. In previous studies (27) in human hepatoma
cells (HepG2), we have demonstrated that Hes-1 functions as a repressor
for transcription of the human GAA gene. Hes-1, binding to a
C class E box (CACGCG) within an intronic repressor element,
down-regulates the human GAA gene expression.
To determine whether the human GAA gene is under
the control of the Notch-1/Hes-1 signaling pathway, we have
investigated the effect of Notch-1 and Hes-1 on expression of the human
GAA gene in HepG2 cells. We have demonstrated the
Notch-1/Hes-1 pathway in HepG2 cells and shown that the human
GAA gene is a downstream target of Notch-1/Hes-1 signaling.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs--
Expression plasmid constructs containing
four copies of repressor element with wild type
(4xwtHes-1/TK-CAT) or mutant Hes-1 binding E box
(4xmutHes-1/TK-CAT) used for co-transfection experiments were
described previously (27) and are shown in Fig. 1A. The expression construct for Hes-1, pcDNA3-wtHes-1, was a gift from Drs. Michael Caudy and Felix Loh (Cornell University Medical College, New York, NY). The expression construct for NICD, cytohN1pcDNA3, was a gift from Prof. Spyros Artavanis-Tsakonas (Massachusetts General
Hospital, Harvard Medical School, Charlestown, MA). All of the plasmids
were prepared and purified for transfection with a Qiagen Maxim Kit
(Qiagen, Valencia, CA).
Cell Culture and Transfection--
HepG2 cells were grown in
Dulbecco's modified Eagle's medium with 10% fetal calf serum and
penicillin/streptomycin (Invitrogen). For
co-transfection experiments, 4xwtHes-1/TK-CAT or
4xmutHes-1/TK-CAT (1.0 µg) were incubated with
plasmid pcDNA3 or cytohN1-pcDNA3 (3.0 µg), together with 10 µl of LipofectAMINE. Expression plasmid pXGH5 for human growth
hormone (0.5 µg) was included as an internal control of the
transfection efficiency. Forty-eight hours later, the cells were
harvested for CAT and hGH activity assays (CAT and hGH enzyme-linked
immunosorbent assay kits, Roche Molecular Biochemicals). CAT activities
were further standardized to hGH activities. For stable transfection,
pcDNA3, cytohN1pcDNA3, or pcDNA3-Hes-1 was transfected into
HepG2 cells with LipofectAMINE. Individual colonies were obtained with
G418 (0.6 mg/ml) selection for 2 weeks. The colonies were grown and
expanded in Dulbecco's modified Eagle's medium with G418 (0.6 mg/ml)
for further assays. Pools of pcDNA3-transfected HepG2 cells were
obtained by G418 selection for 2 weeks and used as controls.
Phosphorothioated Oligonucleotide
Treatment--
Phosphorothioated antisense oligonucleotides of 30mer
in length corresponding to fourth ankyrin repeat within NICD were used for depletion of Notch1 in HepG2 cells. The DNA sequence is
5'-GCCCGCATGCATGATGGCACGACGCCACTG-3' (28). No homology of the sequence
was found with a BLAST search of the GenBankTM data base.
The corresponding phosphorothioated sense oligonucleotides were used as
internal control. All of the oligonucleotides were synthesized and
purified by Lofstrand Labs Limited (Gaithersburg, MD). Oligonucleotides
(2.0 µM) were incubated with LipofectAMINE (5 µg/ml)
(Invitrogen) and overlaid onto the cells as described (20, 29). The
medium containing oligonucleotides-LipofectAMINE complexes was changed
daily for 1 week.
Northern Blot Analysis--
HepG2 cells were transfected with
pcDNA3 or cytohN1pcDNA3 and LipofectAMINE. Total RNA was
extracted at intervals after transfection with TRIzol reagent
(Invitrogen). Northern blot analysis was performed according to
standard procedures. A Hes-1 probe (697 bp) was generated by PCR with
pcDNA3-wtHes-1 as a template with the primers
5'-CCAGTGTCAACACGACACCGGATAAACC-3' (forward) and
5'-GTTGCTGGTGTAGACGGGGATGACAG-3' (reverse).
Western Blot Analysis--
Cell lysates were prepared with
radioimmune precipitation lysis buffer (10 mM Tris-HCl (pH
7.5), 150 mM NaCl, 0.1% SDS, 1.0% Triton X-100, 1.0%
sodium deoxycholate, aprotinin 2.0 µg/ml, leupeptin 2.0 µg/ml,
pepstatin 1.0 µg/ml,
N -p-tosyl-L-lysine
chloromethyl ketone 50 µg/ml, and phenylmethylsulfonyl fluoride 100 µg/ml). Western blot analysis was carried out as described previously
(30, 31). NICD, Hes-1, and GAA were detected using anti-Notch1 antibody
(Upstate Biotechnology, Inc., Lake Placid, NY), anti-Hes-1 antibody (a
gift of Dr. Tetsuo Sudo, Toray Industries, Inc., Kanagawa, Japan), and
anti-hGAA antibody (a gift of Dr. Barry J. Byrne, University of
Florida, Gainesville, FL) respectively. Immunodetection of -catenin
(Santa Cruz Biotechnology, Santa Cruz, CA) was used for loading control.
GAA Enzyme Activity Assay--
HepG2 cells were prepared with
lysis buffer (0.9% NaCl, 0.25% Triton X-100). The GAA and
-hexosaminidase activities of transfected HepG2 cells were assayed
by conversion of the substrates 4-methylumbelliferyl D-glucoside and 4-methylumbelliferyl
N-acetyl- -D-glucosaminide to the fluorescent
product umbelliferone as described (32). Protein concentration of whole
cell lysate was measured with the Bio-Rad protein assay kit (Bio-Rad
Laboratories, Hercules, CA).
 |
RESULTS |
Notch-1/Hes-1 Pathway in HepG2 Cell Line--
Hes-1
has been shown to be a downstream target of Notch-1 signaling in human
cell lines (22). To determine whether Notch-1/Hes-1 signaling is
functional in HepG2 cells, co-transfection experiments were carried out
with reporter gene constructs containing Hes-1 binding sites and NICD
expression plasmid. Expression of the reporter gene linked to the wild
type Hes-1 sites was significantly down-regulated by NICD (Fig.
1B). In contrast, expression
of the reporter gene linked to mutant Hes-1 sites was not affected
(Fig. 1B), suggesting that intact Hes-1 sites are required
for NICD effect.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 1.
The effect of NICD on the expression of the
reporter gene and Hes-1. A, structures of reporter
expression constructs for co-transfection experiments. B,
HepG2 cells were transfected with plasmid pBLCAT2, 4xwtHes-1/TK-CAT,
and 4xmutHes-1/TK-CAT, alone or in combination with pcDNA3 or
cytohN1pcDNA3 at an amount ratio of 1:3. Plasmid pXGH5 was used to
monitor transfection efficiency. CAT activities are normalized to hGH
activities and expressed as a percentage of expression relative to
cells transfected with empty vector pBLCAT2 alone. The bars
represent the mean and standard deviation of CAT activities from at
least three independent transfection experiments. *, p < 0.01 compared with 4xwtHes-1/TK-CAT alone or with pcDNA3.
C, up-regulation of Hes-1 gene expression by
over-expressed NICD. HepG2 cells were transiently transfected with
cytohN1pcDNA3 and total RNA was extracted two h after transfection.
Northern blot analysis was performed with Hes-1 cDNA a probe.
Ethidium bromide staining of 18 S RNA is shown for equal loading
of sample wells. The experiment was repeated at least three
times.
|
|
To establish the relationship between Notch-1 and Hes-1 in HepG2 cells,
NICD was transiently transfected into the cells, and Northern blot
analysis was performed with Hes-1 cDNA as a probe at 2, 6, 12, 24, and 48 h post-transfection. A 2.3-fold up-regulation of the
Hes-1 gene expression by NICD, compared with empty vector, was observed at 2 h post-transfection (Fig. 1C). This
up-regulation, however, was transient and became marginal at later time
points (not shown).
The validity of the Notch-1/Hes-1 pathway in HepG2 cells was further
confirmed by depletion of Notch-1 with phosphorothioated antisense
oligonucleotides of 30mer corresponding to the fourth ankyrin repeat of
NICD. Corresponding phosphorothioated sense oligonucleotide was used as
a control. After treatment for 1 week the depletion of Notch-1 (62%)
was accompanied by a decrease in Hes-1 gene expression, as
shown by the 56% reduction of Hes-1 protein on Western analysis (Fig.
2)

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of NICD antisense oligonucleotide on
Hes-1 gene expression. HepG2 cells were treated
with 2.0 µM sense and antisense oligonucleotides of NICD
in Dulbecco's modified Eagle's medium for 1 week. Western blot
analyses were performed on whole cell extracts. Depletion of Notch-1 by
the antisense oligonucleotide (A) and a decrease of Hes-1
(B) were demonstrated using anti-Notch-1 and anti-Hes-1
antibodies, respectively. -Catenin was used as an internal control.
S, sense oligonucleotides; A, antisense
oligonucleotides.
|
|
Notch-1/Hes-1/GAA Pathway in HepG2 Cell Line--
To
demonstrate the effect of Hes-1 on the endogenous GAA gene,
HepG2 cells were transfected with Hes-1 expression plasmid and stably
transfected colonies were analyzed. Over-expression of Hes-1
down-regulated GAA gene expression, resulting in a decrease in the GAA protein level as shown by Western analysis (Fig.
3, A and B).
Consistent with these results, up to 30% reduction in GAA enzyme
activity was observed after Hes-1 over-expression (Fig. 3C).
Another lysosomal enzyme, -hexosaminidase, used as an internal control, was not affected by over-expressed Hes-1 (Fig. 3C).
Thus, expression of the GAA gene is negatively regulated by
Hes-1 in HepG2 cells.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Effect of Hes-1 on GAA gene
expression. HepG2 cells were transfected with pcDNA3 or
pcDNA3-Hes-1 and stably transfected cell colonies were obtained by
selection with G418. Pools of the G418-selected cells transfected with
pcDNA3 were used as controls. The cell colonies were expanded, and
whole cell extracts were prepared for the following assays.
A, over-expression of ectopic Hes-1 was detected by Western
blot analysis with anti-Hes-1 antibody. Hes-1* indicates
endogenous Hes-1. -Catenin was used as an internal control.
C1, C2, and C3, stable transfected
cell colonies 1, 2 and 3. B, reduced level of GAA protein
(54, 23, and 62% in C1, C2, and C3, respectively) was detected by
Western blot analysis with anti-GAA antibody. C, decreased
GAA activity was detected by enzymatic assay. The results from three
independent experiments are expressed as percentage of control cells
transfected with empty pcDNA3. -Hexosaminidase, a lysosomal
enzyme, was used as an internal control of GAA activity assay. *,
p < 0.01.
|
|
The effect of NICD over-expression in HepG2 cells was similar to that
of Hes-1-negative regulation of the GAA gene expression. HepG2 cells constitutively expressing ectopic NICD were obtained by
transfection with cytohN1pcDNA3 and selection with G418. As shown
in Fig. 4, over-expression of NICD
confirmed by Western blot with anti-Notch1 antibody (Fig.
4A), resulted in a reduced amount of GAA protein (Fig.
4B) and reduced enzyme activity (Fig. 4C). The
data strongly suggest that human GAA is regulated by Notch-1/Hes-1
pathway in HepG2 cells.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of NICD on GAA gene
expression. HepG2 cells were stably transfected with pcDNA3 or
cytohN1pcDNA3A. Whole cells extracts were prepared as described in
Fig. 3. A, elevated NICD was detected by Western blot
analysis with anti-Notch1 antibody. -Catenin was used as an internal
control. C1, C2, and C3, stably
transfected cell colonies 1, 2 and 3. B, reduced level of
GAA protein (41, 74, and 63% in C1, C2, and C3, respectively) was
detected by Western blot analysis with anti-GAA antibody. C,
decreased GAA activity was detected by enzymatic assay.
-Hexosaminidase was also measured as an internal control. *,
p < 0.01.
|
|
 |
DISCUSSION |
GAA is a typical housekeeping gene that is expressed in
every tissue. It has been shown, however, that during development there
are significant quantitative differences in the level of murine GAA
expression in different tissues and even within a particular tissue
(33), suggesting that the gene may be regulated at the transcriptional
level. In humans, both protein and enzyme activity are significantly
higher in newborns compared with adults, again suggesting that the gene
is transcriptionally regulated during development (34). In our previous
studies (27, 35) we identified a cis-acting negative
regulatory element in the first intron of the GAA gene and
demonstrated that transcription factor Hes-1 binds to the element in a
tissue-specific manner and functions as a repressor in HepG2 cells. The
Hes-1 gene and its homologues are immediate downstream genes
of the Notch signaling pathway in many cells. In this study, we provide
evidence of the Notch-1/Hes-1 pathway in HepG2 cells, demonstrating
that the human GAA gene is a downstream target of
Notch-1/Hes-1 signaling. This pathway may contribute to the
developmental control of GAA gene expression.
Several lines of evidence indicate that Hes-1 is under
Notch-1 control in HepG2 cells; depletion of Notch-1 led to a decreased level of Hes-1, whereas over-expression of NICD led to up-regulation of
endogenous Hes-1, which in turn down-regulated the reporter gene
expression through binding to its recognition sequence.
The up-regulation of endogenous Hes-1 transcription by
over-expressed NICD in HepG2 cells, detectable at 2 h
post-transfection, was transient, however; the effect became marginal
afterward. Although several studies have demonstrated that
Hes-1 is activated by constitutively over-expressed NICD
(18, 36, 37), others have reported only marginal or no changes in
Hes-1 gene expression under Notch-1 signaling (38, 39).
Transient activation of Hes-1 gene expression has also been
observed under ligand-activated Notch-1 signaling and retinoic
acid-induced differentiation (40-42). This transient activation of
Hes-1 is most likely due to the ability of the protein to
negatively auto-regulate itself because three stretches of recognition
sequence (N boxes) are present within the promoter of Hes-1
gene (11, 43, 44). This autoregulation loop of Hes-1 gene
expression may act as a regulator for the varied functions of Notch-1
signaling during development (45).
The link between GAA and Notch-1/Hes-1 pathway was established by
demonstrating a repressive effect of both Notch-1 and Hes-1 on the
levels of GAA protein and activity. The effect was not a dramatic one,
which is hardly surprising. After all, only minor differences in the
level of GAA activity separate the most severe rapidly progressive form
of GSDII (Pompe's disease) from milder late-onset variants of
the disease.
Recently, another Hes-related repressor protein, HERP, has been shown
to be a target of Notch-1 signaling, which functions as a heterodimer
partner of Hes-1 (39, 45, 46). Although our data do not rule out the
role of HERP, we believe that Hes-1 rather than HERP is mainly
responsible for the transcriptional repression of the human
GAA gene because the silencer in the GAA gene
contains a recognition sequence a C class E box (CACGCG) preferred by
Hes-1 (46). These new data thus show yet another aspect of the
Notch-1/Hes-1 signaling pathway; demonstrate that regulation of a
so-called housekeeping gene, GAA, may be quite complex; and
suggest that this lysosomal enzyme may have still unrecognized
physiological roles in development.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Current address: Dept. of Anatomy and Cell Biology, George
Washington University, Washington, D. C. 20037.
§
To whom correspondence should be addressed: Clinical Center, Bldg.
10, Rm. 9N244, NIAMS, National Institutes of Health, 9000 Rockville
Pike, Bethesda, MD 20892-1820. Tel.: 301-496-1474; Fax: 301-402-0012;
E-mail: plotzp@mail.nih.gov.
Published, JBC Papers in Press, June 13, 2002, DOI 10.1074/jbc.M204721200
 |
ABBREVIATIONS |
The abbreviations used are:
NICD, Notch-1
intracellular domain;
GAA, acid -glucosidase;
TLE, transducin-like enhancer;
GSDII, glycogen storage disease type II;
CAT, chloramphenicol acetyltransferase;
TK, thymidine kinase;
hGH, human
growth hormone.
 |
REFERENCES |
| 1.
|
Greenwald, I.
(1998)
Genes Dev.
12,
1751-1762[Free Full Text]
|
| 2.
|
Artavanis-Tsakonas, S.,
Rand, M. D.,
and Lake, R. J.
(1999)
Science
284,
770-776[Abstract/Free Full Text]
|
| 3.
|
Mumm, J. S.,
and Kopan, R.
(2000)
Dev. Biol.
228,
151-165[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Mizutani, T.,
Taniguchi, Y.,
Aoki, T.,
Hashimoto, N.,
and Honjo, T.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
9026-9031[Abstract/Free Full Text]
|
| 5.
|
Lecourtois, M.,
and Schweisguth, F.
(1998)
Curr. Biol.
8,
771-774[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Schroeter, E. H.,
Kisslinger, J. A.,
and Kopan, R.
(1998)
Nature
393,
382-386[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Struhl, G.,
and Adachi, A.
(1998)
Cell
93,
649-660[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Weinmaster, G.
(2000)
Curr. Opin. Genet. Dev.
10,
363-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Fisher, A.,
and Caudy, M.
(1998)
Bioessays
20,
298-306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Sasai, Y.,
Kageyama, R.,
Tagawa, Y.,
Shigemoto, R.,
and Nakanishi, S.
(1992)
Genes Dev.
6,
2620-2634[Abstract/Free Full Text]
|
| 11.
|
Feder, J. N.,
Jan, L. Y.,
and Jan, Y. N.
(1993)
Mol. Cell. Biol.
13,
105-113[Abstract/Free Full Text]
|
| 12.
|
Akazawa, C.,
Sasai, Y.,
Nakanishi, S.,
and Kageyama, R.
(1992)
J. Biol. Chem.
267,
21879-21885[Abstract/Free Full Text]
|
| 13.
|
Ishibashi, M.,
Sasai, Y.,
Nakanishi, S.,
and Kageyama, R.
(1993)
Eur. J. Biochem.
215,
645-652[Medline]
[Order article via Infotrieve]
|
| 14.
|
Koyano-Nakagawa, N.,
Kim, J.,
Anderson, D.,
and Kintner, C.
(2000)
Development
127,
4203-4216[Abstract]
|
| 15.
|
Bessho, Y.,
Miyoshi, G.,
Sakata, R.,
and Kageyama, R.
(2001)
Genes Cells
6,
175-185[Abstract]
|
| 16.
|
Jarriault, S.,
Brou, C.,
Logeat, F.,
Schroeter, E. H.,
Kopan, R.,
and Israel, A.
(1995)
Nature
377,
355-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Jarriault, S.,
Le Bail, O.,
Hirsinger, E.,
Pourquie, O.,
Logeat, F.,
Strong, C. F.,
Brou, C.,
Seidah, N. G.,
and Isra l, A.
(1998)
Mol. Cell. Biol.
18,
7423-7431[Abstract/Free Full Text]
|
| 18.
|
Ohtsuka, T.,
Ishibashi, M.,
Gradwohl, G.,
Nakanishi, S.,
Guillemot, F.,
and Kageyama, R.
(1999)
EMBO J.
18,
2196-2207[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Kageyama, R.,
Ohtsuka, T.,
and Tomita, K.
(2000)
Mol. Cells
10,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Zheng, J. L.,
Shou, J.,
Guillemot, F.,
Kageyama, R.,
and Gao, W. Q.
(2000)
Development
127,
4551-4560[Abstract]
|
| 21.
|
Ohtsuka, T.,
Sakamoto, M.,
Guillemot, F.,
and Kageyama, R.
(2001)
J. Biol. Chem.
276,
30467-30474[Abstract/Free Full Text]
|
| 22.
|
Chen, H.,
Thiagalingam, A.,
Chopra, H.,
Borges, M. W.,
Feder, J. N.,
Nelkin, B. D.,
Baylin, S. B.,
and Ball, D. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5355-5360[Abstract/Free Full Text]
|
| 23.
|
Kim, H. K.,
and Siu, G.
(1998)
Mol. Cell. Biol.
18,
7166-7175[Abstract/Free Full Text]
|
| 24.
|
Allen, R. D., 3rd,
Kim, H. K.,
Sarafova, S. D.,
and Siu, G.
(2001)
Mol. Cell. Biol.
21,
3071-3082[Abstract/Free Full Text]
|
| 25.
|
Fisher, A. L.,
and Caudy, M.
(1998)
Genes Dev.
12,
1931-1940[Free Full Text]
|
| 26.
|
Hirschhorn, R.,
and Reuser, A. J.
(2000)
in
The Metabolic and Molecular Bases of Inherited Diseases
(Scriver, C. R.
, Beaudet, A. L.
, Sly, W. S.
, and Valle, D., eds)
, pp. 3389-3420, McGraw-Hill, New York
|
| 27.
|
Yan, B.,
Heus, J., Lu, N.,
Nichols, R. C.,
Raben, N.,
and Plotz, P. H.
(2001)
J. Biol. Chem.
276,
1789-1793[Abstract/Free Full Text]
|
| 28.
|
Ellisen, L. W.,
Bird, J.,
West, D. C.,
Soreng, A. L.,
Reynolds, T. C.,
Smith, S. D.,
and Sklar, J.
(1991)
Cell
66,
649-661[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Zine, A.,
Van De Water, T. R.,
and de Ribaupierre, F.
(2000)
Development
127,
3373-3383[Abstract]
|
| 30.
|
Hoemann, C. D.,
Beaulieu, N.,
Girard, L.,
Rebai, N.,
and Jolicoeur, P.
(2000)
Mol. Cell. Biol.
20,
3831-3842[Abstract/Free Full Text]
|
| 31.
|
Raben, N., Lu, N.,
Nagaraju, K.,
Rivera, Y.,
Lee, A.,
Yan, B.,
Byrne, B.,
Meikle, P. J.,
Umapathysivam, K.,
Hopwood, J. J.,
and Plotz, P. H.
(2001)
Hum. Mol. Genet.
10,
2039-2047[Abstract/Free Full Text]
|
| 32.
|
Hermans, M. M.,
Kroos, M. A.,
van Beeumen, J.,
Oostra, B. A.,
and Reuser, A. J.
(1991)
J. Biol. Chem.
266,
13507-13512[Abstract/Free Full Text]
|
| 33.
|
Ponce, E.,
Witte, D. P.,
Hirschhorn, R.,
Huie, M. L.,
and Grabowski, G. A.
(1999)
Am. J. Pathol.
154,
1089-9106[Abstract/Free Full Text]
|
| 34.
|
Umapathysivam, K.,
Hopwood, J. J.,
and Meikle, P. J.
(2001)
Clin. Chem.
47,
1378-1383[Abstract/Free Full Text]
|
| 35.
|
Yan, B.,
Raben, N., Lu, N.,
and Plotz, P. H.
(2001)
Hum. Genet.
109,
186-190[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Deftos, M. L.,
Huang, E.,
Ojala, E. W.,
Forbush, K. A.,
and Bevan, M. J.
(2000)
Immunity
13,
73-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Sriuranpong, V.,
Borges, M. W.,
Ravi, R. K.,
Arnold, D. R.,
Nelkin, B. D.,
Baylin, S. B.,
and Ball, D. W.
(2001)
Cancer Res.
61,
3200-3205[Abstract/Free Full Text]
|
| 38.
|
Shawber, C.,
Nofziger, D.,
Hsieh, J. J.,
Lindsell, C.,
Bogler, O.,
Hayward, D.,
and Weinmaster, G.
(1996)
Development
122,
3765-3773[Abstract]
|
| 39.
|
Iso, T.,
Sartorelli, V.,
Chung, G.,
Shichinohe, T.,
Kedes, L.,
and Hamamori, Y.
(2001)
Mol. Cell. Biol.
21,
6071-6079[Abstract/Free Full Text]
|
| 40.
|
Kuroda, K.,
Tani, S.,
Tamura, K.,
Minoguchi, S.,
Kurooka, H.,
and Honjo, T.
(1999)
J. Biol. Chem.
274,
7238-7244[Abstract/Free Full Text]
|
| 41.
|
Grynfeld, A.,
Pahlman, S.,
and Axelson, H.
(2000)
Int. J. Cancer.
88,
401-410[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Wakabayashi, N.,
Kageyama, R.,
Habu, T.,
Doi, T.,
Morita, T.,
Nozaki, M.,
Yamamoto, M.,
and Nishimune, Y.
(2000)
J. Biochem. (Tokyo)
128,
1087-1095[Abstract/Free Full Text]
|
| 43.
|
Feder, J. N., Li, L.,
Jan, L. Y.,
and Jan, Y. N.
(1994)
Genomics
20,
56-61[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Takebayashi, K.,
Sasai, Y.,
Sakai, Y.,
Watanabe, T.,
Nakanishi, S.,
and Kageyama, R.
(1994)
J. Biol. Chem.
269,
5150-5156[Abstract/Free Full Text]
|
| 45.
|
Nakagawa, O.,
McFadden, D. G.,
Nakagawa, M.,
Yanagisawa, H., Hu, T.,
Srivastava, D.,
and Olson, E. N.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
13655-13660[Abstract/Free Full Text]
|
| 46.
|
Iso, T.,
Sartorelli, V.,
Poizat, C.,
Iezzi, S., Wu, H. Y.,
Chung, G.,
Kedes, L.,
and Hamamori, Y.
(2001)
Mol. Cell. Biol.
21,
6080-6089[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Chen, A. Zacharek, A. Li, X. Cui, C. Roberts, M. Lu, and M. Chopp
Atorvastatin Promotes Presenilin-1 Expression and Notch1 Activity and Increases Neural Progenitor Cell Proliferation After Stroke
Stroke,
January 1, 2008;
39(1):
220 - 226.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Shen and S. Christakos
The Vitamin D Receptor, Runx2, and the Notch Signaling Pathway Cooperate in the Transcriptional Regulation of Osteopontin
J. Biol. Chem.,
December 9, 2005;
280(49):
40589 - 40598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fujimori, K. Kadoyama, and Y. Urade
Protein Kinase C Activates Human Lipocalin-type Prostaglandin D Synthase Gene Expression through De-repression of Notch-HES Signaling and Enhancement of AP-2{beta} Function in Brain-derived TE671 Cells
J. Biol. Chem.,
May 6, 2005;
280(18):
18452 - 18461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-S. Yeh, R.-H. Hsieh, S.-C. Shen, S.-H. Wang, M.-J. Tseng, C.-M. Shih, and J.-J. Lin
Nuclear {beta}II-Tubulin Associates with the Activated Notch Receptor to Modulate Notch Signaling
Cancer Res.,
November 15, 2004;
64(22):
8334 - 8340.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-S. Yeh, Y.-M. Lin, R.-H. Hsieh, and M.-J. Tseng
Association of Transcription Factor YY1 with the High Molecular Weight Notch Complex Suppresses the Transactivation Activity of Notch
J. Biol. Chem.,
October 24, 2003;
278(43):
41963 - 41969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Fujimori, Y. Fujitani, K. Kadoyama, H. Kumanogoh, K. Ishikawa, and Y. Urade
Regulation of Lipocalin-type Prostaglandin D Synthase Gene Expression by Hes-1 through E-box and Interleukin-1beta via Two NF-kappa B Elements in Rat Leptomeningeal Cells
J. Biol. Chem.,
February 14, 2003;
278(8):
6018 - 6026.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|